Genetron Holdings Ltd Stock Price, News & Analysis

Genetron Holdings Limited (NASDAQ: GTH) hosted a webinar titled "Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment". Keynote speaker Dr. Yuchen Jiao discussed the critical role of early cancer detection and presented the company’s liquid biopsy technology, HCCscreen^TM, which demonstrates 88% overall sensitivity and 93% specificity in liver cancer detection. Dr. Anne Marie Lennon highlighted the benefits of blood testing for identifying early-stage cancers, emphasizing its integration into routine medical care. Genetron continues to advance cancer molecular profiling.

Genetron Holdings Limited (GTH) reported strong preliminary financial results for Q4 and full year 2020, with total revenue of RMB133.9 million (US$20.5 million) for Q4 and RMB424.5 million (US$65.1 million) for the year, marking increases of 30.1% and 31.3% YoY, respectively. The gross margin improved to 62.8% for Q4 and 61.3% for the full year. Notably, the company successfully raised US$256 million in its IPO. For 2021, GTH forecasts a revenue growth of 45-47%, projecting revenues between RMB615 million and RMB625 million.

Genetron Holdings Limited (NASDAQ:GTH) has announced promising results from its HCCscreenTM Investigational Study for early detection of hepatocellular carcinoma (HCC). The study, involving 1,615 individuals, demonstrated an 88% sensitivity and 93% specificity for HCCscreenTM, surpassing the combined ultrasound and alpha-fetoprotein (AFP) method's 71% sensitivity and 95% specificity. Notably, 49% of identified cases were early-stage tumors, indicating a better prognosis. The company plans to initiate a registrational study with the NMPA in Q2 2023.

Genetron Holdings Limited (Nasdaq: GTH), a prominent precision oncology platform in China, has announced management's participation in virtual investor meetings at the 24th Credit Suisse Asian Investment Conference on March 26, 2021. CEO Sizhen Wang will also engage in a fireside chat at 3:00 PM Beijing time. Genetron Health specializes in molecular profiling tests, cancer screening products, and companion diagnostics, leveraging advanced technologies to enhance cancer treatment and management. Interested parties can obtain further details by contacting Credit Suisse sales representatives.

Genetron Holdings Limited (NASDAQ: GTH), a leader in precision oncology in China, announced that its Chief Technology Officer, Dr. Yuchen Jiao, will present at a Science/AAAS Webinar on March 31. The webinar focuses on early cancer screening and the advancements in liquid biopsy profiling which utilize cell-free DNA (cfDNA) for earlier detection of cancers. Key topics will include the clinical importance of early screening, the role of liquid biopsies alongside traditional tests, and recent cfDNA detection methodologies.

Genetron Holdings Limited (NASDAQ:GTH), a leading precision oncology platform in China, announced it will report its unaudited financial results for Q4 and full year 2020 on March 25, 2021, prior to market open. Management will hold a conference call for investors at 8:30 a.m. ET on the same day. Genetron Health specializes in molecular profiling tests and cancer management, partnering with biopharmaceutical companies to enhance treatment options. The company emphasizes its commitment to transforming cancer care through advanced technologies.

Genetron Holdings Limited (Nasdaq: GTH) announced that its research on early liver cancer screening was cited in the "Chinese Anti-Cancer Association Guidelines for Patients with Primary Liver Cancer." The Guidelines highlight the importance of liquid biopsies in early detection, emphasizing the combined detection of mutations and traditional biomarkers. Genetron’s liquid biopsy study, conducted with the National Cancer Center, indicates strong recognition from the expert community. CEO Sizhen Wang stated that technological advancements in the early screening field are promising for improving cancer prevention efforts in China.

Genetron Holdings Limited (Nasdaq: GTH) announced the release of 13 new research findings at the 21st World Conference on Lung Cancer (WCLC), occurring virtually from January 28 to 31. These studies focus on lung cancer characteristics in the Chinese population, including gene mutation and fusion patterns, immunotherapy markers, and bioinformatics models.

Noteworthy studies include the exploration of EGFR and JAK mutations, the mapping of NTRK1 fusions, and the optimization of early lung adenocarcinoma detection methods. These findings underscore Genetron’s capabilities in advancing personalized lung cancer treatment strategies.

Genetron Holdings Limited (Nasdaq: GTH) announced participation at the BTIG Early Cancer Screening, Diagnostics Reimbursement, and Genomic Tools KOL Day on January 22, 2021. Dr. Yunfu Hu, Chief Medical Officer, will present on molecular cancer diagnostics in the U.S. and China, discussing opportunities and challenges from an FDA perspective. Genetron specializes in molecular profiling tests and cancer screening, leveraging advanced technologies to enhance cancer treatment. The company collaborates with biopharmaceutical firms, providing tailored services across the cancer management spectrum.